Tissue Regenix Group PLC Notice of Interim Results (5516W)

TIDMTRX

RNS Number : 5516W

Tissue Regenix Group PLC

02 August 2018

Tissue Regenix Group plc

Notice of Interim Results

Leeds, 02 August 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 June 2018, on Monday 3 September 2018.

Further information regarding an analyst call will follow in due course.

For more Information:

 
 Tissue Regenix Group plc                  Tel: 0330 430 3073 
  Caitlin Pearson Head of Communications    / 07920272 441 
----------------------------------------  ------------------- 
 
 Jefferies International Ltd               Tel: 020 7029 8000 
  Simon Hardy / Christopher Binks 
----------------------------------------  ------------------- 
 
 FTI Consulting                            Tel: 0203 727 1000 
  Brett Pollard / Mo Noonan/ Mary 
  Whittow 
========================================  ===================

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORDFLFBVVFLBBL

(END) Dow Jones Newswires

August 02, 2018 02:02 ET (06:02 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024